Compare Ford Motor Company (F) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Mesoblast Limited — how do they compare? Ford Motor Company trades at $12.3 (market cap $48.33B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Ford Motor Company is far larger — about 26.7× Mesoblast Limited's market cap, and Ford Motor Company pays a 4.95% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Mesoblast Limited for 14 Days on average.
| F | MESO | |
|---|---|---|
Market Cap | $48.33B | $1.81B |
Volume | 33,572,159 | 240,620 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $20.96 |
52-Week Low | $11.21 | $13.19 |
Typical Hold Time | 104 Days | 14 Days |
Enterprise Value | $180.29B | $1.89B |
Dividend Yield | 4.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.25, down 0.2% with bearish technical signals. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Despite $187.3B revenue in 2025, net income was -$8.18B with negative margins. Analyst consensus is mixed with 38% buy ratings and a $15.90 price target. Recent news highlights sales declines and production challenges, though the company maintains strong cash flow from operations.
Ford faces significant headwinds including declining sales, negative profitability, and high debt levels. The stock offers value with low P/E (11.21) and P/S (0.26) ratios, but execution risks and competitive pressures from Asian automakers pose challenges. The dividend provides income support, but investors should weigh fundamental weaknesses against valuation appeal.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
